Related Experiment Video
Updated: Aug 2, 2025

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
Published on: July 17, 2018
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
Emily M J Fennell1, Lucas J Aponte-Collazo1, Wimal Pathmasiri2
1Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Abstract:
ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes following ClpP activation, the exact mechanism by which ClpP activation leads to broad anti-cancer activity has yet to be fully elucidated. In this study, we utilized a multi-omics approach to identify the ClpP-dependent proteomic, transcriptomic, and metabolomic changes resulting from ONC201 or the TR compound TR-57 in triple-negative breast cancer cells. Applying mass spectrometry-based methods of proteomics and metabolomics, we identified ∼8,000 proteins and 588 metabolites, respectively. From proteomics data, 113 (ONC201) and 191 (TR-57) proteins significantly increased and 572 (ONC201) and 686 (TR-57) proteins significantly decreased in this study. Gene ontological (GO) analysis revealed strong similarities between proteins up- or downregulated by ONC201 or TR-57 treatment. Notably, this included the downregulation of many mitochondrial processes and proteins, including mitochondrial translation and mitochondrial matrix proteins. We performed a large-scale transcriptomic analysis of WT SUM159 cells, identifying ∼7,700 transcripts (746 and 1,100 significantly increasing, 795 and 1,013 significantly decreasing in ONC201 and TR-57 treated cells, respectively). Less than 21% of these genes were affected by these compounds in ClpP null cells. GO analysis of these data demonstrated additional similarity of response to ONC201 and TR-57, including a decrease in transcripts related to the mitochondrial inner membrane and matrix, cell cycle, and nucleus, and increases in other nuclear transcripts and transcripts related to metal-ion binding. Comparison of response between both compounds demonstrated a highly similar response in all -omics datasets. Analysis of metabolites also revealed significant similarities between ONC201 and TR-57 with increases in α-ketoglutarate and 2-hydroxyglutaric acid and decreased ureidosuccinic acid, L-ascorbic acid, L-serine, and cytidine observed following ClpP activation in TNBC cells. Further analysis identified multiple pathways that were specifically impacted by ClpP activation, including ATF4 activation, heme biosynthesis, and the citrulline/urea cycle. In summary the results of our studies demonstrate that ONC201 and TR-57 induce highly similar and broad effects against multiple mitochondrial processes required for cell proliferation.
Insights
ClpP activators ONC201 and TR-57 significantly impact mitochondrial processes in triple-negative breast cancer cells. This multi-omics study reveals shared proteomic, transcriptomic, and metabolomic changes, elucidating their anti-cancer mechanisms.
Area of Science:
- Molecular Biology
- Cancer Research
- Systems Biology
Background:
- ClpP activators like ONC201 show anti-cancer potential in clinical trials for solid tumors.
- The precise mechanism of ClpP activation's broad anti-cancer effects remains incompletely understood.
- Understanding these mechanisms is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To comprehensively identify ClpP-dependent proteomic, transcriptomic, and metabolomic changes induced by ONC201 and TR-57.
- To elucidate the molecular mechanisms underlying the anti-cancer activity of ClpP activators in triple-negative breast cancer (TNBC).
- To compare the multi-omics responses to ONC201 and TR-57 to identify shared pathways.
Main Methods:
- Utilized a multi-omics approach combining mass spectrometry-based proteomics and metabolomics.
- Performed large-scale transcriptomic analysis on wild-type (WT) SUM159 cells and ClpP-null cells.
- Applied Gene Ontology (GO) analysis to interpret proteomic and transcriptomic data.
Main Results:
- Identified significant proteomic and transcriptomic alterations, with substantial overlap between ONC201 and TR-57 treatments.
- Observed downregulation of mitochondrial processes, including translation and matrix proteins, and related transcripts.
- Detected shared metabolic shifts, such as increased α-ketoglutarate and decreased L-serine, and identified impacted pathways like ATF4 activation and heme biosynthesis.
Conclusions:
- ONC201 and TR-57 induce highly similar, broad molecular changes in TNBC cells, primarily affecting mitochondrial functions essential for proliferation.
- The findings provide a deeper mechanistic understanding of ClpP activation as an anti-cancer strategy.
- This study highlights the utility of multi-omics approaches in dissecting complex drug responses.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...

